春季卡他性角结膜炎:发病机制及药物治疗研究进展  

Vernal keratoconjunctivitis:research progress in pathogenesis and treatment

作　　者：许菲[1] 宋剑涛[1] XU Fei;SONG Jiantao(Department of Ocular Surface Disease,Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)

机构地区：[1]中国中医科学院眼科医院眼表疾病科,北京100040

出　　处：《中华临床免疫和变态反应杂志》2025年第1期64-68,共5页Chinese Journal of Allergy & Clinical Immunology

基　　金：中国中医科学院眼科医院中央高水平中医医院项目(GSP1-08)。

摘　　要：春季卡他性角结膜炎(vernal keratoconjunctivitis,VKC)是一种主要累及儿童的、严重的、双眼反复发作的慢性过敏性角结膜炎,可导致视力严重下降甚至致盲。目前其发病原因仍不明确,传统治疗依赖于局部激素及免疫抑制剂,这类药物长期使用副作用较大,且对重症患者疗效不佳。本文拟对VKC的发病机制进行探讨、对药物治疗研究进展进行总结。Vernal keratoconjunctivitis(VKC)is one kind of severe ocular allergic diseases that occurs primarily in children.It is characterized by bilateral,recurrent,and chronic inflammation of cornea and conjunctiva that may lead to loss of visual acuity and blindness.The pathogenesis of VKC is still unclear.The traditional treatment of VKC is dependent on topical hormones and immunosuppressive drugs.Long-term use of these kinds of medicines has significant side effects and poor efficacy among severe cases.The aim of this article is to explore the pathogenesis of VKC and to summarize the progresses on research in the field of its drug therapy.

关 键 词：春季卡他性角结膜炎 发病机制 治疗 奥马珠单抗 

分 类 号：R777.31[医药卫生—眼科]